We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > otilimab

News List

GSK’s COVID-19 antibody shows potential in older patients pharmatimes
March 01, 2021
GlaxoSmithKline (GSK) has reported Phase II results for its investigational monoclonal antibody otilimab in hospitalised COVID-19 patients – and the data is mixed.
First UK patient given GSK’s experimental arthritis drug in COVID-19 trial pharmatimes
September 30, 2020
A patient in Manchester is the first in the UK to be treated in a new COVID-19 trial investigating the use of an experimental arthritis drug, otilimab, for severe lung disease related to the novel coronavirus.
Phase III programme for the use otilimab for rheumatoid arthritis launched europeanpharmaceuticalreview
July 08, 2019
A Phase III clinical development programme testing otilimab in patients with RA has begun.